Form D · Biotechnology

IMV Inc.

Dartmouth, A5 · CIK 0001734768

Offering snapshot reported Jan 3, 2022 · SEC filing

Reported sold
$0
Offering amount: $750K
Investors reported
2
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 17, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 3, 2022Initial$0No comparison2SEC filing
May 18, 2020Initial$3,567,607No comparison1SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-427645
The additional $749,998.00 may be received upon the exercise of the warrants sold inside or outside the U.S.
Each warrant is exercisable for either 56,818 or 113,636 common shares at an exercise price of $1.32 per common share until December 17, 2031.

Source: Form D, filed Jan 3, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Bailey Director
Jeremy Graff Executive
Julia Gregory Director
James Hall Director
Andrew Hall Executive
Michael Kalos Director
Kyle Kuvalanka Director
Pierre Labbe Executive
Frederic Ors Director, Executive
Wayne Pisano Director
Andrew Sheldon Director
Shermaine Tilley Director
Markus Warmuth Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
130 Eileen Stubbs Ave. Suite 19
Dartmouth, A5, B3B 2C4